RU58841

It get the scalp-level effect of an anti-androgen without the systemic sexual, mood, or hormonal side effects that

Finasteride and

Dutasteride can cause in a meaningful minority of users. It's the option people reach for when they want to keep their hair but don't want to gamble with their libido, mental clarity, or fertility. It's also the option women with pattern hair loss reach for when oral anti-androgens are off the table due to side effects, pregnancy plans, or contraception conflicts.

Deep-dive

Androgenetic alopecia is driven by DHT, a more potent androgen converted from testosterone by 5-alpha-reductase, binding to androgen receptors inside scalp hair follicle cells (especially the dermal papilla cells at the base of each follicle). In genetically susceptible people, this binding shifts the gene expression program of the follicle, shortens the anagen (growth) phase, lengthens the resting telogen phase, and progressively shrinks the follicle until it produces shorter, finer, lighter hairs and eventually stops producing visible hair at all. This is the same biology that drives the classic male temple-and-crown pattern and the diffuse central thinning more typical in women.

There are three ways to interrupt the process. You can reduce DHT systemically by inhibiting 5-alpha-reductase (finasteride, dutasteride). You can stimulate the follicle to stay in anagen via a parallel pathway (

Minoxidil (oral & topical)). Or you can block DHT at the receptor level, locally, where it actually does the damage. RU58841 is the third approach.

Mechanistically, RU58841 is a non-steroidal competitive antagonist at the androgen receptor. It has comparable potency to hydroxyflutamide (the active metabolite of flutamide, an oral anti-androgen used in prostate cancer) but is engineered for topical use. The molecule has a short half-life in vivo (under an hour) and is rapidly metabolised by the liver via N-dealkylation. The practical consequence: when applied topically, it occupies receptors at the application site, but any drug that escapes into circulation gets cleared too fast to meaningfully antagonise androgen receptors elsewhere, the testes, prostate, brain. This is the engineering goal of any topical anti-androgen and it's the strongest theoretical case for using RU over an oral 5-AR inhibitor.

The animal data is consistent and strong. The Uno 1997 stumptailed macaque study (stumptailed macaques are the primate model of androgenetic alopecia, they go bald in a frontal pattern that looks like male pattern baldness) tested 0.5%, 1%, 3%, and 5% RU58841 solutions topically for 6 months, then continued the 5% and 0.5% groups out to 12-24 months. The 5% group showed marked increases in hair density, thickness, and length within 3 months, a 2-3 fold increase in terminal-size anagen follicles by month 5, and continued progressive regrowth out to 7 months that was maintained as long as treatment continued. The 3% solution gave moderate effects in only one of five animals. 1% and 0.5% were much weaker. Withdrawal of treatment led to hair loss returning within 3 months. No systemic effects were detected at any dose. This is the cleanest dose-response data we have and it's the reason 5% became the standard concentration.

The 1997 human scalp graft study (De Brouwer et al, Br J Dermatol) grafted balding scalp samples from men with AGA onto nude mice, then exposed the mice to testosterone to drive androgen-dependent hair loss in the grafts. RU58841 partially restored hair production in the human grafts despite the testosterone challenge. This is the only published controlled study of RU58841 on human follicles in vivo, and it confirmed the mechanism translates from primates to human tissue.

The ProStrakan Phase II human trial (running around 2004-2005, never published in full as a peer-reviewed paper) reportedly showed equivalent or better hair count gains versus finasteride over 6 months in men with AGA, with no significant changes in serum DHT, testosterone, LH, or FSH. The lack of a published Phase III dataset is the central evidentiary weakness of this compound. Most of what we know about human efficacy and safety comes from a small Phase II program, animal data, and several decades of accumulated user reports. The combination of those is suggestive but it's not the same as a registered Phase III trial. Anyone considering RU should understand that gap clearly.

Why was it dropped? Not because it failed safety or efficacy endpoints in any documented way. ProStrakan deprioritised the program for business reasons (the hair loss market was viewed as crowded and the molecule's IP position wasn't strong enough to justify the cost of full development). No other company has picked it up. This is annoying for users but it's an important distinction, the compound wasn't pulled because of a discovered harm signal.

Women. RU58841 hasn't been studied in dedicated female trials. Mechanistically there's a reasonable case it should work for female pattern hair loss, which involves similar follicular androgen sensitivity even though circulating androgens in women are much lower. The 2025 JAAD review of antiandrogen therapy for female pattern hair loss discusses RU58841 alongside topical clascoterone and oral spironolactone as topical antiandrogen options that may have a place for women who can't tolerate or don't want oral options. The honest read: the mechanism translates, the dose probably doesn't need to be higher than in men (and may need to be lower given the much lower androgen drive), and the systemic anti-androgen concern is more relevant for women of reproductive age because anti-androgen exposure to a male fetus is the main pregnancy concern with this drug class. If you're pregnant, trying to conceive, or breastfeeding, do not use it. If you're a postmenopausal woman or on reliable contraception, the risk profile is closer to that of a man using it.

Systemic absorption is the real question. Topical application is designed to minimise systemic exposure, but it doesn't eliminate it, especially with daily use of a 5% solution in an ethanol-PG vehicle that increases penetration. The animal pharmacokinetic data (Cousty-Berlin 1994) shows the parent molecule has a roughly 6-hour plasma half-life and its main metabolite RU59416 (which makes up about 93% of measured metabolites in rat) persists around 24 hours and has some anti-androgenic activity of its own. None of this has been characterised properly in chronic human use. The published macaque and ProStrakan data showed no measurable change in serum hormones, but those were 6-month timepoints. What happens at 5 or 10 years of daily 5% scalp application has never been studied in any species. This is the honest unknown.

Stacking. Most users combine RU58841 with

Minoxidil (oral & topical), which targets the growth side of the equation rather than the androgen side. The two mechanisms are complementary and the combination is the standard stack. Some users layer oral finasteride or dutasteride on top for systemic DHT reduction, and use RU to push scalp coverage further. This is overkill for most people and reintroduces the systemic side effect risk that RU was supposed to avoid. The cleanest defensible stack is RU58841 plus topical or low-dose oral minoxidil.

RU58841 vs topical finasteride. The two compounds occupy similar territory but solve the systemic problem differently. Topical finasteride is the same molecule as oral finasteride delivered through the scalp, it inhibits 5-alpha-reductase locally so less DHT gets produced at the follicle. RU58841 doesn't touch DHT production, it blocks the receptor where DHT acts. Both end up with less DHT signalling at the follicle, just through different machinery.

The practical difference is in how cleanly each stays local. The 2022 Phase III topical finasteride trial using a 0.25% spray showed scalp DHT reduction of around 50% with serum DHT reduction of around 34%. A separate P-3074 pharmacokinetic study using the same 0.25% formulation found 60-70% serum DHT reduction at standard dosing, almost identical to the oral tablet. So topical finasteride isn't actually scalp-only, it leaks meaningfully into circulation, and the systemic exposure scales with the concentration and amount applied. Ultra-low concentrations (0.005-0.02%) can get systemic absorption near zero but efficacy drops with it.

RU58841 in the published macaque and ProStrakan Phase II data showed no measurable shift in serum testosterone, DHT, LH, or FSH at 5% topical, and the short plasma half-life argues for cleaner local-only action. We don't have a modern head-to-head trial comparing the two on serum hormones or hair count, so the comparison rests on cross-study inference, which is messy.

The honest tradeoff: topical finasteride has the evidence base (Phase III trials, decades of clinical use, consistent product quality through compounding pharmacies and approved telehealth providers), but it does meaningfully shift serum DHT at standard doses. RU58841 has the stronger theoretical case for zero systemic anti-androgen activity but rests on a Phase II evidence base and grey-market sourcing. For most people the smarter starting point is topical finasteride at a low-to-moderate concentration (0.025-0.1%). RU makes sense if topical finasteride has been tried and the systemic profile isn't clean enough, or if you specifically want receptor-level blockade rather than substrate reduction.

Dosage:

• Standard concentration: 5% solution, applied topically to the scalp once daily. This is the concentration used in the macaque and human studies and the one with the most data behind it. Lower concentrations (3%, 2.5%) work but the dose-response data suggests 5% is where the effect plateaus

• Daily dose: 50 mg of RU58841 per day for men (1 mL of a 5% solution). Women with pattern hair loss can start at 25-50 mg/day, depending on the area being treated and skin sensitivity. There's no benefit to going higher than 5%, the receptor occupancy plateaus and you just irritate the scalp more

• Vehicle: 70% ethanol + 30% propylene glycol is the standard mix and the one used in the original studies. Ethanol drives penetration, PG keeps the drug in solution and slows evaporation. If you're sensitive to PG (some people get contact dermatitis), the alternative is K&B solution (a PG-free oil-based vehicle) but absorption is slightly lower. Pre-mixed solutions from research-chemical vendors save the hassle of weighing powder but quality varies, prefer vendors who publish third-party HPLC purity testing

• Application: Apply to a clean, dry scalp, part the hair and target the actual scalp surface rather than the hair shafts. Anything that lands on hair won't absorb. Most people use 1 mL spread across the affected zones (typically the frontal third and crown). Let it dry fully (10-15 minutes) before lying down or applying anything else. Wash hands after application

• Timing: Once daily is enough. The original twice-daily protocol in the ProStrakan trials hasn't shown a clear advantage over once daily and doubles the irritation risk. If stacking with topical minoxidil, separate the two by 10-15 minutes so each has time to absorb. Most people apply RU in the morning and minoxidil at night

• Stability: RU58841 in ethanol/PG solution is reasonably stable at room temperature for a few months but degrades faster in heat and light. Keep your bottle in a cool, dark place. Make small batches if you're mixing your own powder, 1-2 months of solution at a time, rather than a year's worth

• Cycling: Unlike some peptides, RU doesn't need to be cycled. The receptor antagonism doesn't downregulate the receptor itself. Stopping leads to hair loss returning within roughly 3 months as the follicles are no longer protected

Here's what you can expect:

Side effects & risks:

• Scalp irritation is the most common issue. Redness, dryness, itching, occasional flaking, contact dermatitis. The PG component is the usual culprit and the ethanol can dry the scalp out. Switching to a lower PG concentration, using a PG-free vehicle, or alternating days helps. A 2% ketoconazole shampoo a couple of times a week reduces inflammation and is a useful adjunct

• Initial shed. First 4-8 weeks. Looks bad, isn't bad, resolves on its own as follicles cycle back into anagen. Don't quit during this phase

• Systemic anti-androgen effects (lowered libido, mood changes, gynecomastia, reduced morning erections, fatigue). Rare at standard 5% topical doses but documented anecdotally and biologically plausible given the metabolite kinetics. Risk goes up with higher concentrations, larger application areas (whole-scalp coverage in advanced loss), broken skin, or co-application of penetration enhancers. If you notice these symptoms, reduce the dose or stop, and they typically resolve within weeks. A small subset of users seem to be more sensitive to systemic exposure for unclear reasons

• Pregnancy is the hard contraindication. Anti-androgens can interfere with the development of male fetal genitalia. Do not handle the powder or solution if you are pregnant or trying to conceive. Women using RU should be on reliable contraception, and male partners of pregnant women should be cautious about transfer (wash hands thoroughly, don't share towels, let solution fully dry before contact)

• Drug interactions are not well characterised. Theoretical concerns with any other anti-androgen (spironolactone, bicalutamide, oral finasteride/dutasteride at higher doses) and with compounds that affect liver metabolism

• Long-term safety data is essentially non-existent. No published study has followed users beyond 6-12 months of daily use. The molecule was designed for limited-duration treatment of a specific condition, and chronic decades-long use is an extrapolation. This is a real unknown and the main reason RU sits firmly in the research chemical bucket rather than the approved medication bucket

• Product quality risk. Because RU is grey-market, what you buy may not be what's on the label. Some vendors sell underdosed, contaminated, or degraded material. Always prefer vendors who publish third-party HPLC or LC-MS purity testing, and store your solution properly to prevent degradation. This is one of the biggest practical risks and it's avoidable with sourcing diligence

• Acne and skin changes at the application site. Some users report a transient acne flare in the first few weeks as the scalp adjusts. Usually resolves